Agranulocytosis and Central Line Complications

The National Inpatient Sample (NIS) 2019 database was utilized to conduct this study. Data was extracted by utilizing the International Classification of Diseases, 10th Revision (ICD-10) codes. The inclusion criteria for this study were patients with a primary diagnosis of agranulocytosis secondary to cancer chemotherapy (ASCC) who underwent CVC insertion during the hospitalization. Exclusion criteria for this study were patients with iatrogenic pneumothorax secondary to central line insertion, patients with blood product administration, patients with platelet product administration, and patients with sepsis. The primary outcome studied was in-hospital mortality and was identified by the variable 'DIED' from the NIS database.
Data processing and statistical analysis was done using the SPSS version 26 software package (IBM Inc.m Armonk, New York). Categorical data was compared using Pearson's Chi-squared test, and continuous variables were compared using the independent samples t-test. Multivariate regression utilizing binomial logistic regression was performed with in-hospital mortality as the primary outcome. Multivariate regression was conducted to study the effects of CVC insertion on in-hospital mortality, with covariates including age, sex, race, primary payer status, and select medical comorbidities from the Charlson comorbidity index. A p-value of <0.05 was considered significant for all statistical comparisons.